Depletion of MNX1 stimulates the cytotoxic T cell‐mediated anti‐tumor immunity and enhances the therapy effect of cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) blockade. This evidence concerns the gene CTLA4 and neoplasm.